Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aprameya EngineeringNSE:APRAMEYA -0.11%43 Earnings Yield (Joel Greenblatt) % is 2.63% as of Mar. 2026, which is 34% below its 10-year median of 4.01. GuruFocus rates NSE:APRAMEYA with a GF Score™ of 43/100. The stock has 6 warning signs investors should review. Among 849 Medical Devices & Instruments companies, Aprameya Engineering ranks better than 66.08% on this metric.
Aprameya Engineering's Enterprise Value for the quarter that ended in Mar. 2026 was ₹3,947.5 Mil.
Aprameya Engineering's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹109.3 Mil. Aprameya Engineering's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 2.63%.
The historical rank and industry rank for Aprameya Engineering's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
NSE:APRAMEYA'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 2.27 Med: 4.01 Max: 12.51
Current: 4
During the past 7 years, the highest Earnings Yield (Joel Greenblatt) of Aprameya Engineering was 12.51%. The lowest was 2.27%. And the median was 4.01%.
NSE:APRAMEYA's Earnings Yield (Joel Greenblatt) % is ranked better than 66.08% of 849
companies
in the Medical Devices & Instruments industry
Industry Median: 0.83
vs NSE:APRAMEYA: 4.00
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Aprameya Engineering's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 19.84%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Aprameya Engineering Earnings Yield (Joel Greenblatt) % Related Terms
Aprameya Engineering Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Aprameya Engineering's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Aprameya Engineering's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aprameya Engineering Earnings Yield (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aprameya Engineering's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Aprameya Engineering's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Aprameya Engineerings Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Mar. 2026 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 2.63% mean?
Aprameya Engineering (NSE:APRAMEYA) has a Earnings Yield (Joel Greenblatt) % of 2.63% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Aprameya Engineering and its competitors. This is 34% below median its historical median of 4.01. Over the past decade, Aprameya Engineering's Earnings Yield (Joel Greenblatt) % has ranged from 2.27 to 12.51. According to the industry distribution chart, Aprameya Engineering ranks #288 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 33.9%.
Is Aprameya Engineering's Earnings Yield (Joel Greenblatt) % too high?
Aprameya Engineering's current Earnings Yield (Joel Greenblatt) % of 2.63% is 34% below median its 10-year median of 4.01. Over the past 10 years, this metric has ranged from a low of 2.27 to a high of 12.51. The Medical Devices & Instruments industry median Earnings Yield (Joel Greenblatt) % is 0.83. Aprameya Engineering's value of 2.63% is 216.9% above this industry median. Based on the distribution chart, Aprameya Engineering ranks #288 out of 849 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Aprameya Engineering has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Aprameya Engineering's Earnings Yield (Joel Greenblatt) % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Aprameya Engineering ranks #288 out of 849 companies for Earnings Yield (Joel Greenblatt) %. This puts Aprameya Engineering in the upper half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 0.83. Aprameya Engineering's value of 2.63% is 216.9% above this benchmark. Historically, Aprameya Engineering's own Earnings Yield (Joel Greenblatt) % has ranged from 2.27 to 12.51 over the past decade. While the company's 10-year median is 4.01 vs. the industry median of 0.83, Aprameya Engineering has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median Earnings Yield (Joel Greenblatt) % among Medical Devices & Instruments companies is 0.83, based on 849 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aprameya Engineering's current Earnings Yield (Joel Greenblatt) % of 2.63% is 216.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Aprameya Engineering and its competitors. For the Medical Devices & Instruments industry, the median Earnings Yield (Joel Greenblatt) % is 0.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aprameya Engineering's current Earnings Yield (Joel Greenblatt) % is 2.63%, which is 34% below median its own 10-year median of 4.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprameya Engineering stock overvalued right now?
Aprameya Engineering (NSE:APRAMEYA) has a current Earnings Yield (Joel Greenblatt) % of 2.63%. The current Earnings Yield (Joel Greenblatt) % is 2.63%, which is 34% below median its 10-year median of 4.01 and 216.9% above the Medical Devices & Instruments industry median of 0.83. Aprameya Engineering's overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Aprameya Engineering (NSE:APRAMEYA), the current Earnings Yield (Joel Greenblatt) % is 2.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aprameya Engineering Ltd is engaged in the business of installation, set up & maintenance of Intensive Care Units (ICU), Neonatal Intensive Care Units (NICU), Pediatric Intensive Care Units (PICU), Operation Theatre, dialysis centres and prefabricated structure ward (hereinafter referred to as Healthcare Infrastructure projects) in the hospitals and medical care centers on turnkey basis with the supply of high-value healthcare equipment and diagnostic equipment to private hospitals, Government hospitals, and medical practitioners. The company has two Business segments: Trading of Medical support Equipment (Trading Sales) and Supplies for Infra Projects for health care sectors (Turnkey project supplies). Key revenue is generated from Trunkey Project Supply.
43GF Score
Get the complete analysis for NSE:APRAMEYA
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:APRAMEYA has been successfully added to your 
